Executive summary
United States Patent 9,616,114 is centered on a two-stage, dual-inducible genetic program in a live, genetically engineered Salmonella platform: (i) secretion of a sialic acid O-acyl transferase (and dependent O-antigen transferase features in dependent claims) under a first heterologous inducible promoter, followed by (ii) secretion of a distinct, independently inducible antitumor enzyme (e.g., tyrosinase; amino-acid degrading enzymes such as tryptophanase/asparaginase) under a second inducible promoter, after tumor-site colonization under non-lethal conditions. The claim set is broad at the functional level (secreted enzyme products, inducible promoter classes, tumor colonization/tropism, formulation, serum half-life), while the dependent claims lock in specific promoter/integration details (MarA induced by acetyl salicylic acid; tet/arabinose/hypoxia/SOS/X-ray/mitomycin-responsive promoters; mar regulon architecture) and specific antitumor payloads (tyrosinase; tryptophanase; asparaginase; amino-acid degrading enzymes; “Lic3A, lic3B and sigA” elements) plus physical/behavioral attributes (size, width, increased CO2 resistance, surface antigen patterning via induced rfb/O-antigen clusters).
Critical patent landscape takeaway: the intellectual property value of 9,616,114 is driven more by (a) its specific sequencing and induction architecture (two distinct inducible controls with non-overlapping promoters for two secretion events after colonization) and (b) its tumor payload enablement (active-form secretion of defined enzyme classes) than by the use of Salmonella alone, which is heavily prior-art saturated. The enforceability risk is elevated because live bacteria cancer therapy, inducible expression systems, secreted enzymes, and tumor-colonizing Salmonella are all well represented in earlier patents and publications. The estate’s litigation leverage will likely hinge on claim construction around “secreted” (active form), “O-acyl transferase for action on external components,” promoter inducibility by specific non-natural inducers, and the requirement for distinct first/second gene sets and distinct inducible promoters.
United States Patent 9,616,114 Claims Analysis and US Patent Landscape
What does US Patent 9,616,114 claim at the highest level?
Core invention (Claim 1). A live genetically engineered Salmonella that is adapted for human or animal administration and colonization under non-lethal conditions, then executes a post-colonization, two-step secretion program:
-
First gene product module (sialic acid O-acyl transferase pathway)
- At least one first gene produces a secreted first gene product comprising sialic acid O-acyl transferase.
- Expression is under at least one heterologous first inducible promoter.
-
Second gene product module (antitumor enzyme payload)
- At least one second gene produces a secreted functional antitumor enzyme gene product.
- Expression is under a second heterologous inducible promoter, distinct from the first promoter.
- The first gene is distinct from the second gene (i.e., separate genetic constructs or separate coding sequences).
-
Functional sequencing requirement
- After colonization: first module secretion occurs “for action on external components of the live genetically engineered Salmonella bacterium.”
- After colonization: second module secretion occurs “for action against tumor cells.”
Key legal/claim-construction pressure points likely to matter in litigation or freedom-to-operate (FTO):
- “Secreted”: whether the claim requires secretion outside the bacterial cell envelope (not merely periplasmic localization), and whether secretion must be measurable/external to bacteria.
- “Action on external components”: interpret whether this is limited to bacterial surface components or could encompass broader extracellular substrates.
- “Non-lethal conditions”: whether colonization must be non-lethal for the host or non-lethal for the bacterium itself.
- “Heterologous inducible promoter” and “pharmacological inducer agents not naturally found in humans” (in dependent claims): whether promoter-inducer compatibility is a material limitation.
- Distinct promoters/gene sets: whether a single genetic locus with combinatorial control could still infringe if promoters are distinct but regulated via shared machinery.
How do dependent claims 2–5 expand the sialic acid and antitumor payload scope?
O-antigen transferase adjunct (Claim 2)
- Adds that the first gene product further produces O-antigen transferase.
- This narrows to constructs that couple sialyl/O-acyl transfer logic to O-antigen remodeling.
Defined antitumor enzymes (Claims 3–5)
- Claim 3: antitumor payload comprises tyrosinase, secreted in active form.
- Claim 4: antitumor payload comprises an amino-acid degrading enzyme secreted in active form with anti-tumor activity against tumors colonized by the bacterium.
- Claim 5: enumerates at least one enzyme selected from tryptophanase and asparaginase, secreted in active form.
Critical breadth note:
The base claim recites “functional antitumor enzyme gene product,” while dependent claims specify enzymatic identities and insist on active form secretion. In practice, this can raise validity/enforcement questions: if the specification supports many enzyme candidates broadly, dependent claim specificity can still anchor interpretation that “secreted in active form” is a meaningful limitation. For competitors, designing with inactive/attenuated forms or relying on non-enzyme mechanisms can be an avoidance path.
What promoter architecture limitations exist (Claims 6–10, 13–14)?
The claims include both promoter class flexibility and specific exemplar promoter systems.
Specific example: MarA induced by acetyl salicylic acid (Claim 6)
- First inducible promoter comprises MarA induced by acetyl salicylic acid (aspirin).
Broad inducible promoter responsive list (Claim 7)
- First inducible promoter responsive to at least one of:
- tet
- arabinose
- hypoxia
- cellular SOS response promoter
- X-rays
- mitomycin
Multi-promoter and multi-product scaling (Claims 8–10, 13)
- Claim 8: plurality of first inducible promoters for plurality of first inducible gene products.
- Claim 9: first module can use plurality of heterologous inducible promoters with different pharmacological inducers not naturally found in human tissue.
- Claim 10: plurality of first genes under different promoters produces a plurality of different surface antigen patterns depending on presence of different inducers.
- Claim 13: heterologous first inducible promoter comprises a single promoter effective to promote a plurality of first genes producing multiple different secreted products.
mar regulon/operator-region architecture (Claim 14)
- Promoter includes a regulon comprising mar promoter/operator region, MarR negative regulator, MarA positive regulator, upstream of start codon, for promoting expression of an rfb cluster.
Critical enforcement implication:
The presence of Claim 14’s mar regulon details creates a tether: even if Claim 1 is broad, a competitor copying the platform but using a different promoter system can avoid dependent claim coverage. Conversely, if a design uses MarA-based regulation, Claim 14 could narrow and strengthen infringement arguments.
How do tumor targeting, formulation, and PK extensions change the infringement analysis (Claims 11–12)?
Selective tropism and treatment link (Claim 11)
- Requires selective tropism for at least one tumor type.
- Requires that the secreted functional antitumor enzyme gene product is effective for treating that tumor type.
- Requires the bacterium is provided within a pharmaceutically acceptable formulation.
Serum half-life enhancement (Claim 12)
- Adds formulation requirement and asserts that secretion of the first module product increases serum half-life compared with bacteria lacking the secreted first gene product.
Critical practical note:
These claims can become high-friction in litigation because serum half-life and tumor treatment effectiveness are performance-linked limitations. Competitors can argue noninfringement by different PK profile design or different sequencing of induced secretion. Validity can also be attacked if prior art already taught similar immune evasion or serum persistence via bacterial surface modification or sialylation-like strategies.
Do physical and environmental tolerance claims materially narrow the estate (Claims 16–17, 20)?
- Claim 16: maximum size about 650 nm.
- Claim 17: width less than 401 nm.
- Claim 20: selected to have higher CO2 resistance than wild type Salmonella.
Claim strategy consequence:
These are measurable phenotype limits that can narrow infringement and create evidentiary burdens. For defendants, it is easier to take non-overlapping strain engineering routes. For plaintiffs, phenotype measurement consistency across batches and assay methods becomes central.
What are the likely “hot spots” in Claim 18 (Lic3A, lic3B, sigA)?
- Claim 18: first gene product further comprises Lic3A, lic3B and sigA.
This is a highly specific genetic/biological feature. Its inclusion suggests the patent’s sialic acid/O-acyl pathway module likely ties to a particular glycan modification or localization machinery. In infringement, missing one of these factors can avoid the dependent claim. In validity, it can distinguish from broader sialic acid or capsule modifications in earlier art unless those specific genes were already described in connection with inducible secretion and tumor colonization.
How strong is the patent estate for a live genetically engineered Salmonella antitumor therapy?
What prior art categories are most relevant (and most likely to challenge novelty/non-obviousness)?
Across US practice, 9,616,114 sits at the intersection of multiple crowded fields:
-
Live attenuated or engineered bacteria for cancer
Prior patents and academic literature widely document tumor colonization by Salmonella strains and use in oncolytic/therapeutic formats.
-
Inducible expression systems in bacteria for in vivo control
Systems responding to tetracycline (tet), arabinose, hypoxia, SOS response, DNA damage agents, radiation, or mitomycin are classic inducible control examples.
-
Two-stage or multi-module secretion / logic-gated payload expression
Logic circuits (multiple promoters, stage-gating, sequential expression) are commonly used in synthetic biology, including microbial therapeutics.
-
Surface modification strategies for serum persistence and immune evasion
Prior art on bacterial glycan modification (including sialic acid-like modifications, O-antigen changes, capsule-like effects) is extensive.
Net effect:
Novelty likely resides in the specific combination and sequencing in Claim 1:
- a tumor-colonizing Salmonella executing two independently inducible secretion events after colonization, one targeting external components of the bacteria, the other secreting a functional antitumor enzyme against tumor cells.
Even so, obviousness risk remains high because each component can be assembled from known pieces, with motivation supplied by known immune persistence, safety, and controlled payload expression rationales.
What patents protect the dual-inducible, secreted enzyme Salmonella approach in the US?
What to expect in the US patent landscape (structure-level mapping)
Because 9,616,114’s claims are not limited to a single promoter/enzyme choice, competitors often face overlapping rights from four US patent clusters:
-
Salmonella tumor targeting and non-lethal colonization platform patents
Look for patents covering engineered Salmonella strains adapted for tumor colonization and delivery in mammals.
-
Inducible promoter patents and promoter-sensor combinations
Companies with large bacterial inducible control portfolios may have patents on tet/arabinose/hypoxia/SOS-based systems in vivo.
-
Secretion and functional enzyme payload patents
Patents on secretion of enzymes in active form for tumor therapy (including tyrosinase and amino-acid degrading enzymes) are likely to overlap.
-
Bacterial surface glycoengineering patents
Patents on sialylation/acyl transferase type activities, O-antigen transferase modules, and serum half-life/immune evasion via glycan remodeling.
Practical legal consequence:
Freedom-to-operate typically requires checking whether an accused product practices:
- the specific inducible sequencing in Claim 1,
- the active-form secretion requirement (depending on which dependent claims are asserted), and
- the specific promoter architecture or surface modification elements (for dependent claim coverage).
When does US Patent 9,616,114 lose exclusivity and when can generics or competitors enter?
What matters for expiration and patent term
US patent expiration depends on:
- filing date (20-year term from earliest effective non-provisional filing, adjusted for PTA),
- terminal disclaimers,
- and any patent term adjustments or reductions.
However, no filing/issuance details were provided here. Without the application filing date, any analysis of the exact expiration date would be incomplete.
What FDA status is likely tied to this patent: IND, biologics pathway, or investigational bacterial therapy?
This is a live genetically engineered bacterial product with dual inducible secretion. Such products typically go through the biologics pathway (CDER vs CBER depends on construct and regulatory classification) and require IND authorization. No FDA product name, application number, or regulatory milestone was provided. A mapping to Orange Book or BPCIA is therefore not possible from the claim text alone.
How does US Patent 9,616,114 compare with competing bacterial oncology IP?
Competitive positioning: what aspects are differentiated
Relative to broad “engineered Salmonella secreting a payload” patents, 9,616,114 differentiates by:
- Two distinct inducible promoters driving two different secreted modules after colonization.
- A first module involving sialic acid O-acyl transferase and optionally O-antigen transferase.
- Explicit action timing and substrate location: first module acts on external components of the bacteria, second module acts on tumor cells.
- Payload specificity in dependents: tyrosinase and amino-acid degrading enzymes including tryptophanase/asparaginase in active form.
- Promoter examples and architectural details: MarA/aspirin and mar regulon/rfb cluster.
Likely competitive avoidance patterns
A competitor could reduce exposure by:
- Using a single inducible promoter for both modules (risking non-infringement of distinct promoter requirements).
- Avoiding secretion “in active form” for the antitumor payload.
- Using different promoter sensors or inducers not covered by the claim’s specific promoter list (especially where dependent claims enumerate inducible responsiveness).
- Avoiding the claimed sialic acid O-acyl transferase / O-antigen transferase linkage.
Patent litigation posture and Paragraph IV / biosimilar risk
No litigation history, ANDA/505(b)(2), or biosimilar challenge data was provided. A targeted assessment of Paragraph IV timing or biosimilar risk is not possible without:
- the identity of the corresponding marketed or clinical product,
- the Orange Book list of patents tied to that product, and
- any known Hatch-Waxman litigation docket references.
Key Takeaways
- US Patent 9,616,114’s enforceable core is the two-stage, dual-inducible secretion architecture in a tumor-colonizing live Salmonella platform.
- The sialic acid O-acyl transferase module is not merely an immune-evasion claim; it includes a post-colonization sequencing requirement and “action on external components” language that can be central to infringement.
- Dependent claims add practical narrowing levers: MarA/aspirin, tet/arabinose/hypoxia/SOS/X-rays/mitomycin, specific antitumor enzymes (tyrosinase; tryptophanase/asparaginase), and active-form secretion.
- Physical phenotype limitations (size/width) and environmental tolerance (CO2 resistance) create additional potential non-infringement defenses.
- The landscape is crowded around live bacterial oncology, inducible control, and secreted enzyme payloads, so validity and claim construction will likely focus on the patent’s specific combination and sequencing elements.
FAQs
- How do courts typically interpret “secreted” and “active form” for bacterial enzyme payloads in US patent claims?
- What promoter design changes most reliably avoid claims requiring distinct heterologous inducible promoters for two gene sets?
- How do “action on external components” limitations affect infringement for bacterial surface modification technologies?
- Which design choices reduce risk of infringing enzyme-dependent claims like tyrosinase or tryptophanase/asparaginase in active secretion form?
- How does adding phenotypic constraints (size/width/CO2 resistance) shift the evidentiary burden in infringement disputes?
References
- US Patent 9,616,114 (claim text provided in prompt).
